Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 28, Issue 2, 2010, Pages 193-201

  Hanrahan, Emer O ^a   Lin, Heather Y ^a   Kim, Edward S ^a   Yan, Shaoyu ^a   Du, Danny Z ^a   McKee, Kathryn S ^a   Tran, Hai T ^a   Lee, J Jack ^a   Ryan, Anderson J ^a   Langmuir, Peter ^a   Johnson, Bruce E ^a   Heymach, John V ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CARBOPLATIN; CYTOKINE; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PACLITAXEL; SYNAPSIN I; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MODULATION; MONOTHERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CYTOKINES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 74949090109     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.4279     Document Type: Article

References (44)

1. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
2. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364, 1996
3. Herbst RS, Onn A, Sandler A: Angiogenesis and lung cancer: Prognostic and therapeutic implications. J Clin Oncol 23:3243-3256, 2005
4. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027, 2005
5. Benelli R, Lorusso G, Albini A, et al: Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr Pharm Des 12:3101-3115, 2006
6. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
7. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
8. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007
9. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
10. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
11. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
12. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
13. Demetri G, van Oosterom AT, Garrett C, et al: Improved survival and sustained clinical benefit with SU11248 (SU) in pts with GIST after failure of imatinib mesylate (IM) therapy in a phase III trial. 2006 Gastrointestinal Cancers Symposium, San Francisco, CA, January 26-28, 2006 (abstr 8)
14. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005
15. Norden-Zfoni A, Desai J, Manola J, et al: Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 13:2643-2650, 2007
16. Ebos JM, Lee CR, Christensen JG, et al: Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 104:17069-17074, 2007
17. Longo R, Gasparini G: Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol 60:151-170, 2007
18. Peña C, Gatzemeier U, Lathia C, et al: Plasma biomarkers in a phase II trial of sorafenib in advanced non-small cell lung cancer. AACR-NCIEORTC Molecular Targets and Cancer Therapeutics Conference, San Francisco, CA, October 22-26, 2007 (abstr B18)
19. Nikolinakos P, Altorki N, Guarino M, et al: Analyses of plasma cytokine/angiogenic factors (C/ AFs) profile during preoperative treatment with pazopanib (GW786034) in early-stage non-small cell lung cancer. J Clin Oncol 26:414s, 2008 (suppl; abstr 7568)
20. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, et al: Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16:558-565, 2005
21. Deprimo SE, Bello CL, Smeraglia J, et al: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins. J Transl Med 5:32, 2007
22. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007
23. Shaked Y, Henke E, Roodhart JM, et al: Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14: 263-273, 2008
24. Heymach JV, Paz-Ares L, De Braud F, et al: Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26:5407-5415, 2008
25. Heymach JV, Johnson BE, Prager D, et al: Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25:4270-4277, 2007
26. Natale RB, Bodkin D, Govindan R, et al: Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a two-part, double-blind, randomized phase II study. J Clin Oncol 27:2523-2529, 2009
27. Liang KY, Zeger SL: Longitudinal data analysis using generalized linear models. Biometrika 73:13-22, 1986
28. Kiura K, Nakagawa K, Shinkai T, et al: A randomized, double-blind, phase IIa dose-finding study of vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 3:386-393, 2008
29. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24, 2006
30. Elting J, Bigwood D, Brown-Shimer S, et al: Biomarkers associated with clinical outcomes in TARGETs, a phase III single-agent, placebo-controlled study of sorafenib in advanced renal cell carcinoma. 97th Annual Meeting of the American Association for Cancer Research, Washington, DC, April 1-5, 2006 (abstr 2909)
31. Drevs J, Medinger M, Mross K, et al: Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol 23:192s, 2005 (suppl; abstr 3002)
32. Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006
33. Hutson TE, Davis ID, Machiels JH, et al: Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 26:261s, 2008 (suppl; abstr 5046)
34. Bukowski RM, Eisen T, Szczylik C, et al: Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. J Clin Oncol 25:240s, 2007 (suppl 18S; abstr 5023)
35. Hong KH, Ryu J, Han KH: Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 105: 1405-1407, 2005
36. Mizukami Y, Jo WS, Duerr EM, et al: Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 11:992-997, 2005
37. Mihaylova Z, Ludovini V, Gregorg V, et al: Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients. J Buon 12:105-111, 2007
38. Cox G, Jones JL, Walker RA, et al: Angiogenesis and non-small cell lung cancer. Lung Cancer 27:81-100, 2000
39. Seandel M, Noack-Kunnmann K, Zhu D, et al: Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen. Blood 97:2323-2332, 2001
40. Heissig B, Hattori K, Dias S, et al: Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kitligand. Cell 109:625-637, 2002
41. Ahn GO, Brown JM: Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: Role of bone marrow-derived myelomonocytic cells. Cancer Cell 13:193-205, 2008
42. Du R, Lu KV, Petritsch C, et al: HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13:206-220, 2008
43. Jin DK, Shido K, Kopp HG, et al: Cytokinemediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 12:557-567, 2006
44. Dowlati A, Gray R, Sandler AB, et al: Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab: An Eastern Cooperative Oncology Group Study. Clin Cancer Res 14:1407-1412, 2008